Shares of Cytori Therapeutics Inc. (NASDAQ:CYTX) saw unusually-strong trading volume on Wednesday . Approximately 285,755 shares were traded during mid-day trading, an increase of 131% from the previous session’s volume of 123,660 shares.The stock last traded at $2.01 and had previously closed at $2.03.

Several equities research analysts have commented on CYTX shares. Maxim Group set a $5.00 target price on shares of Cytori Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 31st. Zacks Investment Research downgraded shares of Cytori Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, July 29th. Finally, Roth Capital reaffirmed a “buy” rating and issued a $11.00 target price on shares of Cytori Therapeutics in a research note on Tuesday, June 28th.

The company’s market capitalization is $42.42 million. The stock has a 50 day moving average of $2.09 and a 200 day moving average of $2.68.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Cytori Therapeutics (NASDAQ:CYTX) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.04. The company had revenue of $1.10 million for the quarter, compared to the consensus estimate of $2.50 million. Cytori Therapeutics had a negative net margin of 203.79% and a negative return on equity of 210.47%. The company’s revenue for the quarter was down 31.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.06) earnings per share. On average, analysts expect that Cytori Therapeutics Inc. will post ($1.29) EPS for the current fiscal year.

A hedge fund recently bought a new stake in Cytori Therapeutics stock. Cambridge Associates LLC MA ADV purchased a new stake in shares of Cytori Therapeutics Inc. (NASDAQ:CYTX) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,000 shares of the company’s stock, valued at approximately $852,000. Cytori Therapeutics comprises 0.4% of Cambridge Associates LLC MA ADV’s investment portfolio, making the stock its 19th largest position. Hedge funds and other institutional investors own 18.48% of the company’s stock.

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

5 Day Chart for NASDAQ:CYTX

Receive News & Ratings for Cytori Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc. and related companies with's FREE daily email newsletter.